Intranasal administration of IFN-α/β inhibits the development of visceral tumor metastases

Journal of Interferon and Cytokine Research

Volumn 17, Issue 1, 1997, Pages 31-36

  Kaido, Thomas J ^a,b  

^a Institut de Recherches Scientifiques sur le Cancer   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; RECOMBINANT ALPHA INTERFERON;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B CELL LEUKEMIA; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FRIEND LEUKEMIA; INTRANASAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA CELL LINE; MALE; MELANOMA CELL; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SURVIVAL TIME; T CELL LYMPHOMA; VISCERA;

ANIMALIA; MURINAE;

EID: 0031038725     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1997.17.31     Document Type: Article

References (23)

1. EINHORN, S., and GRANDER, D. (1996). Why do so many cancer patients fail to respond to Interferon therapy? J. Interferon Cytokine Res. 16, 275-281.
2. SCHAFER, T.W., LIEBERMAN, M., COHEN, M., and CAME, P.E. (1972). Interferon administered orally: Protection of neonatal mice from lethal virus challenge. Science 176, 1326-1327.
3. HAYDEN, F.G., ALBRECHT, J.K., KAISER, D.L., and GWALTNEY, J.M., JR. (1986). Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon. N. Engl. J. Med. 314, 71-75.
4. BROD, S., KHAN, M., KERMAN, R.H., and PAPPOLLA, M. (1995). Oral administration of human or murine interferon suppresses relapses and modifies adoptive transfer in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 58, 61-69.
5. CUMMINS, J.M., TOMPKINS, M.B., OLSEN, R.G., TOMPKINS, W.A., and LEWIS, M.G. (1988). Oral use of human alpha interferon in cats. J. Biol. Response Mod. 7, 513-523.
6. DHINGRA, K., DUVIC, M., HYMES, S., McLAUGHLIN, P., ROTHBERG, J., and GUTTERMAN, J.U. (1993). A phase-I clinical study of low-dose oral interferon-α. J. Immunother. 14, 51-55.
7. KINNULA, V., CANTELL, K., and MATTSON, K. (1990). Effect of inhaled natural interferon-alpha on diffuse bronchioalveolar carcinoma. Eur J. Cancer 267, 740-741.
8. BOCCI, V. (1991). Absorption of cytokines via oropharyngeal-associated lymphoid tissues. Does an orthodox route improve the therapeutic index of interferon? Clin. Pharmacokinet. 21, 411-417.
9. ser. J. Interferon Res. 12, 411-413.
10. BAYLEY, D., TEMPLE, C., CLAY, V., STEWARD, A., and LOWTHER, N. (1995). The transmucosal absorption of recombinant human interferon-α B/D hybrid in the rat and rabbit. J. Pharm. Pharmacol. 47, 721-724.
11. FLEISCHMANN, W.R., KORAN, S., and FLEISCHMANN, M.C. (1992). Orally administered interferons exert their white blood cell suppressive effects via a novel mechanism. Proc. Soc. Exp. Biol. Med. 201, 200-207.
12. HALME, M., MAASILTA, P., MATTSON, K., and CANTELL, K. (1994). Pharmacokinetics and toxicity of inhaled human natural interferon-beta in patients with lung cancer. Respiration 61, 105-107.
13. MAASILTA, P., HALME, M., MATTSON, K., and CANTELL, K. (1991). Pharmacokinetics of inhaled recombinant and natural alpha interferon. Lancet 337, 371.
14. KUPER, C.F., LOORNSTRA, P.J., HAMELEERS, D.M.H., BIEWENGA, J., SPIT, B.H., DUIJVESTIJN, A.M., VAN BREDA VRIESMAN, P.J.C., and SMINIA, T. (1992). The role of nasopharyngeal lymphoid tissue. Immunol. Today 13, 219-223.
15. TOVEY, M.G., BEGON-LOURS, J., and GRESSER,I. (1974). A method for the large scale production of potent interferon preparations. Proc. Soc. Exp. Biol. Med. 146, 809-815.
16. GRESSER, I., TOVEY, M.G., BANDU, M.-T., MAURY, C., and BROUTY-BOYE, D. (1976). Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. I. Rapid evolution of encephalomyocarditis virus infection. J. Exp. Med. 144, 1305-1311.
17. GRESSER, I., KAIDO, T.J., MAURY, C., WOODROW, D., MOSS, J., and BELARDELLI, F. (1994). Interaction of IFN-α/β with host cells essential to the early inhibition of Friend erythroleukemia visceral metastases. Int. J. Cancer 57, 604-611.
18. MEISTER, A., UZE, G., MOGENSEN, K.E., GRESSER, I., TOVEY, M.G., GRUTIER, M., and MEYER, F. (1986). Biological activities and receptor binding of two human recombinant and natural alpha interferon. J. Gen. Virol 67, 1633-1643.
19. UZE, G., LUFTALLA, G., BANDU, M.T., PROUDHON, D., and MOGENSEN, K.E. (1992). Behavior of a cloned murine interferon-alpha/beta receptor expressed in homospecific or heterospecific background. Proc. Natl. Acad. Sci. USA 89, 4774-4778.
20. + T cells and IFN-α/β. Int. J. Cancer 57, 538-543.
21. GRESSER, I., CARNAUD, C., MAURY, C., SALA, A., EID, P., WOODROW, D., MAUNOURY, M.-T., and BELARDELLI, F. (1991). Host humoral and cellular immune mechanisms in the continued suppression of Friend erythroleukemia metastases after interferon-α/β treatment in mice. J. Exp. Med. 173, 1193-1203.
22. ser. J. Natl. Cancer Inst. 81, 1062-1068.
23. KAIDO, T.J., GRESSER, I., MAURY, C., MAUNOURY, M.-T., VIGNAUX, F., and BELARDELLI, F. (1993). Sensitized T lymphocytes render DBA/2 beige mice responsive to IFN-α/β therapy of Friend erythroleukemia visceral metastases. Int. J. Cancer 54, 475-181.